- Home
- SB vs IVA Comparison
SB vs IVA Comparison
Compare SB & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SB
- IVA
- Stock Information
- Founded
- SB 2007
- IVA 2011
- Country
- SB Monaco
- IVA France
- Employees
- SB N/A
- IVA N/A
- Industry
- SB Marine Transportation
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- SB Consumer Discretionary
- IVA Health Care
- Exchange
- SB Nasdaq
- IVA Nasdaq
- Market Cap
- SB 395.3M
- IVA 359.6M
- IPO Year
- SB 2008
- IVA 2020
- Fundamental
- Price
- SB $3.73
- IVA $2.98
- Analyst Decision
- SB Strong Buy
- IVA Strong Buy
- Analyst Count
- SB 1
- IVA 4
- Target Price
- SB $5.00
- IVA $10.50
- AVG Volume (30 Days)
- SB 376.4K
- IVA 17.9K
- Earning Date
- SB 07-28-2025
- IVA 03-26-2025
- Dividend Yield
- SB 5.38%
- IVA N/A
- EPS Growth
- SB N/A
- IVA N/A
- EPS
- SB 0.67
- IVA N/A
- Revenue
- SB $290,312,000.00
- IVA $14,591,573.00
- Revenue This Year
- SB N/A
- IVA $15.38
- Revenue Next Year
- SB $13.41
- IVA $24.22
- P/E Ratio
- SB $5.42
- IVA N/A
- Revenue Growth
- SB N/A
- IVA N/A
- 52 Week Low
- SB $3.02
- IVA $1.53
- 52 Week High
- SB $6.22
- IVA $4.05
- Technical
- Relative Strength Index (RSI)
- SB 51.14
- IVA 39.58
- Support Level
- SB $3.56
- IVA $3.00
- Resistance Level
- SB $3.91
- IVA $3.40
- Average True Range (ATR)
- SB 0.09
- IVA 0.22
- MACD
- SB -0.02
- IVA -0.04
- Stochastic Oscillator
- SB 48.57
- IVA 0.00
About SB Safe Bulkers Inc ($0.001 par value)
Safe Bulkers Inc is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain and iron ore, along international shipping routes for consumers of marine drybulk transportation services. The company employs its vessels on both period time charters and spot time charters, according to the assessment of market conditions, with consumers of marine drybulk transportation services.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.